The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
 
Natasha B. Leighl
Consulting or Advisory Role - Xcovery
Research Funding - Array BioPharma (Inst); Guardant Health (Inst); Novartis (Inst); Roche Canada (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Nektar; Roche
 
Mary Weber Redman
Consulting or Advisory Role - Ignyta; Ignyta
 
Naiyer A. Rizvi
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences; Bellicum Pharmaceuticals; Brooklyn ImmunoTherapeutics; Gritstone Bio
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca/MedImmune; Bellicum Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Editas Medicine; EMD Serono; Genentech/Roche; GlaxoSmithKline; Illumina; Janssen; Lilly; Merck Sharp & Dohme; NeoGenomics Laboratories; Novartis; Regeneron; Takeda
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - Royalties related to patent filed by MSKCC, Determinants of cancer response to immunotherapy (PCT/US2015/062208) licensed to Personal Genome Diagnostics
 
Fred R. Hirsch
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Genentech; Lilly; Loxo; Merck; Novartis; Oncocyte; Pfizer; Roche
Research Funding - Abbvie (Inst); Amgen (Inst); Biodesix (Inst); Merck (Inst); Mersana (Inst); Rain Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - EGFR FISH and IHC for prediction of outcome in patients treated with EGFR inhibitors (Inst)
 
Philip C. Mack
Honoraria - Guardant Health
Consulting or Advisory Role - Amgen; AstraZeneca; Guardant Health
Research Funding - Boehringer Ingelheim
 
Lawrence Howard Schwartz
Consulting or Advisory Role - Novartis; Regeneron
Research Funding - Boehringer Ingelheim (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Varian Medical Systems
 
James Lloyd Wade
Employment - Johnson & Johnson (I)
Stock and Other Ownership Interests - Abbott (I); Celgene; GlaxoSmithKline (I); Johnson & Johnson (I); Novartis (I)
Consulting or Advisory Role - New Century Health
 
William Johnson Irvin
Research Funding - Altor BioScience (Inst); Boston Biomedical (Inst); Genomic Health (Inst); Luitpold Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst)
 
Sreekanth Reddy
No Relationships to Disclose
 
Jeffrey Crawford
Consulting or Advisory Role - Amgen; AstraZeneca; BeyondSpring Pharmaceuticals; Coherus Biosciences; Enzychem Lifesciences; G1 Therapeutics; GlaxoSmithKline; Merck; Mylan; Pfizer; Roche; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Genentech (Inst); Helsinn Healthcare (Inst)
 
Jeffrey D. Bradley
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune
Travel, Accommodations, Expenses - Mevion Medical Systems
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; EMD Serono; Foundation Medicine; G1 Therapeutics; Genentech/Roche; Lilly; Novartis; Pfizer; Takeda
Research Funding - Advaxis (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Merck (Inst); Regeneron (Inst); Takeda (Inst)
 
Suresh S. Ramalingam
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Genentech/Roche; Lilly/ImClone; Loxo; Merck; Nektar; Takeda; Tesaro
Research Funding - Abbvie (Inst); Advaxis (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genmab (Inst); Merck (Inst); Merck (Inst); Pfizer (Inst); Takeda (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Jieling Miao
No Relationships to Disclose
 
Katherine Minichiello
No Relationships to Disclose
 
David R. Gandara
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; CellMax Life (Inst); Guardant Health (Inst); Inivata; IO Biotech (Inst); Lilly; Merck; OncoCyte (Inst); Pfizer; Roche/Genentech
Research Funding - AstraZeneca/MedImmune (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Roy S. Herbst
Leadership - Junshi Pharmaceuticals
Consulting or Advisory Role - Abbvie; ARMO Biosciences; AstraZeneca; Biodesix; Bolt Biotherapeutics; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Genmab; Halozyme; Heat Biologics; I-Mab; Immunocore; Infinity Pharmaceuticals; Junshi Pharmaceuticals; Lilly; Loxo; Merck; Midas Health Analytics; Mirati Therapeutics; Nektar; Neon Therapeutics; NextCure; Novartis; Pfizer; Sanofi; Seagen; Shire; Spectrum Pharmaceuticals; Symphogen; Takeda; TESARO; Tocagen
Research Funding - AstraZeneca; Genentech/Roche; Lilly; Merck
 
Vassiliki Papadimitrakopoulou
Employment - Pfizer
Honoraria - Roche
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bolt Biotherapeutics; Bristol-Myers Squibb; Clovis Oncology; Exelixis; G2 Innovation; Genentech; Genentech; Gritstone Bio; Janssen; Leads Biolabs; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
Karen Kelly
Honoraria - Merck
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Inivata; Merck; Novartis; Pfizer; Regeneron; Symphogen
Research Funding - Abbvie (Inst); Astellas Pharma; Bristol-Myers Squibb; EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Regeneron (Inst); Tizona Therapeutics, Inc.; Transgene
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Merck; Regeneron